Allergan plc  (AGN)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 332
 Employees 10,500
 Revenues (TTM) (Millions $) 16,096
 Net Income (TTM) (Millions $) -2,479
 Cash Flow (TTM) (Millions $) 211
 Capital Exp. (TTM) (Millions $) 479

Allergan Plc
Allergan, Inc. is a technology-driven, global health care company that develops and commercializes specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets. We are a pioneer in specialty pharmaceutical research, targeting products and technologies related to specific disease areas such as glaucoma, retinal disease, dry eye, psoriasis, acne and movement disorders. Additionally, we develop and market aesthetic-related pharmaceuticals and over-the-counter products. Within these areas, we are an innovative leader in therapeutic and other prescription products, and to a limited degree, over-the-counter products that are sold in more than 100 countries around the world. We are also focusing research and development efforts on new therapeutic areas, including gastroenterology, neuropathic pain and various types of cancer.

We were originally incorporated in California in 1948 and became known as Allergan Corporation in 1950. In 1977, we reincorporated in Delaware. In 1980, we were acquired by SmithKline Beecham plc (then known as SmithKline Corporation). From 1980 through 1989, we operated as a wholly-owned subsidiary of SmithKline and in 1989 we again became a stand-alone public company through a spin-off distribution by SmithKline.

On June 29, 2002, we completed the spin-off of our optical medical device business to our stockholders. The optical medical device business consisted of two businesses: our ophthalmic surgical products business, which developed, manufactured and marketed products that included artificial lenses for the eye, called intraocular lenses, and equipment for cataract and refractive eye surgery; and our contact lens care products business, which developed, manufactured and marketed a broad range of products for use with every available type of contact lens. The spin-off was effected by contributing our optical medical device business to a newly formed subsidiary, Advanced Medical Optics, Inc., and issuing a dividend of Advanced Medical Optics’ common stock to our stockholders. The Internal Revenue Service ruled that the transaction qualified as tax-free for Allergan and our stockholders for U.S. federal income tax purposes, with the exception of cash received for fractional shares. The common stock of Advanced Medical Optics began trading publicly on the New York Stock Exchange on July 1, 2002 under the symbol “AVO.” Following the spin-off, we continue to own and operate our specialty pharmaceutical business and Advanced Medical Optics owns and operates what was formerly our optical medical device business. We have no ownership interest in Advanced Medical Optics. Our consolidated financial statements and related notes reflect the financial position, results of operations and cash flows of the optical medical device business as a discontinued operation.


We face significant competition in all of our markets worldwide. Numerous companies are engaged in the development, manufacture and marketing of health care products competitive with those that we manufacture. Our major eye care competitors include Alcon Laboratories, Inc., Bausch & Lomb, Pfizer, Novartis Ophthalmics and Merck & Co., Inc. These competitors have equivalent or, in most cases, greater resources than us. Our skin care business competes against a number of companies, including among others, Dermik, a division of Aventis, Galderma, a joint venture between Nestle and L’Oreal, Bristol-Myers Squibb, Schering-Plough Corporation, Johnson & Johnson and Hoffman-La Roche Inc., all of which have greater resources than us. In the market for neuromodulators, we have three competitors, including Beaufour Ipsen Ltd., which sells products in Europe, Latin America, Asia, Australia and New Zealand, Elan Pharmaceuticals, which sells products in the United States and Europe, and a Chinese entity which sells products in limited countries in Asia and Latin America. In marketing our products to health care professionals, pharmacy benefits management companies, health care maintenance organizations, and various other national and regional health care providers and managed care entities, we compete primarily on the basis of product technology and price. We believe that we compete favorably in our product markets.

   Company Address: Clonshaugh Business and Technology Park Dublin 0
   Company Phone Number: 261-7000   Stock Exchange / Ticker: NYSE AGN

Customers Net Income grew by AGN's Customers Net Profit Margin fell to

6.28 %

4.84 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AGRX   -10.13%    
JNJ   -1.98%    
MRK   -3.19%    
PFE        0.2% 
TEVA        4.28% 
AMGN   -3.28%    
• View Complete Report

Open Text Corp

Profits Rose by 200 % at the Open Text Corp during the financial period ending December 31 2022

The company published notable income growth of 200 % to $0.96 per share, on fading Sales of -22.882 % to $810.92 millions in the most recent fiscal period, relative to the previous year.

World Wrestling Entertainment Inc

Contraction in profitability regardless of Increase in demand at the company over the fourth quarter of 2022

World Wrestling Entertainment Inc reported declining eps on increasing revenue in the fourth quarter of 2022, where Sales increased by 4.849 % to $325.30 millions relative to $310.26 millions on a year-over-year basis, while EPS plummeted by -42.12 % to $0.42 per share, income per share was $0.72 in fourth quarter of 2021.

Rave Restaurant Group Inc

Income per Share Unaffected at the Wholesale company in the October to December 25 2022 span

For the October to December 25 2022 span Rave Restaurant Group Inc net profit per share remained unaffected of $0.02 per share compare to $0.02 a year before and Income per Share remained unaffected from $0.02 per share from the prior reporting period.

Sales grew by 6.306 % to $2.87 millions from $2.70 millions in the corresponding reporting period a year before and sequentially Sales decreased by -4.626 % from $3.01 millions.

Good Times Restaurants Inc

Deficit In spite of Sales elevation at the company over the financial period closing Dec 27 2022

For the fiscal span ending December 27 2022 Good Times Restaurants Inc Diminishing Returns have swelled of $-0.01 per share compare to $0.03 a year before and earnings per share improved from $-0.10 per share from the prior reporting season.

Sales grew barely by 1.452 % to $33.39 millions from $32.92 millions in the corresponding reporting season a year before and sequentially Sales decreased by -5.104 % from $35.19 millions.

Berry Global Group Inc

Decrease in Income at the Berry Global Group Inc over the financial interval closing December 31 2022

Sales and profitability went down in sympathy in the first quarter of 2022, where profitability decreased by -2.3 % to $0.85 per share and revenue by -14.358 % year on year. Revenue were at $3.06 billions in proportion to $3.57 billions in the financial interval ending December 31 2021.


Allergan Plc's Segments
Eye Care Pharmaceuticals
 Segment     of total Revenue
Skin Care
 Segment     of total Revenue
 Segment     of total Revenue
Total Specialty Pharmaceuticals
 Segment     of total Revenue
Alphagan P & Alphagan
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Breast Aesthetics
 Segment     of total Revenue
Facial Aesthetics
 Segment     of total Revenue
Total Medical Devices
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Allergan Plc does not provide revenue guidance.

Earnings Outlook
Berry Global Group Inc does not provide earnings estimates.

Geographic Revenue Dispersion
United States
Asia Pacific
Latin America


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

CRKR's Profile

Stock Price

CRKR's Financials

Business Description


Charts & Quotes

CRKR's News


CRKR's Competitors

Customers & Markets

Economic Indicators

CRKR's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071